Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Discovery summit 2013 john howl news releaseA Step Away From Cell-Penetrating Peptide Drug Discovery: Interview with: John Howl


Published on

A Step Away From Cell-Penetrating Peptide Drug Discovery: Interview with: John Howl, Professor of Molecular Pharmacology, Director of Pantechnia - Research Institute in Healthcare Science, University of Wolverhampton, a speaker at the marcus evans Discovery Summit 2013, on the use of cell-penetrating peptides in drug discovery.

  • Be the first to comment

  • Be the first to like this

Discovery summit 2013 john howl news releaseA Step Away From Cell-Penetrating Peptide Drug Discovery: Interview with: John Howl

  1. 1. A Step Away From Cell-Penetrating Drug Discovery towards peptides as useful chemical There is also the possibility of employing entities, now that cost and stability bioactive cell-penetrating peptides, challenges have largely been overcome. termed bioportides, to achieve similar results. Peptides can also be used to There is a lot of potential in the pipeline, target protein interfaces and so cell-penetrating peptides that need to modulate discrete signalling pathways be converted into new drugs. They have that may be modified in disease a unique ability to traverse cell processes. membranes and deliver other bioactive entities into the cell interior. They can This molecular mimicry can in turn be made more cell type-specific by interfere with pathological events, adding on homing motifs, or can be including angiogenesis, which are viable chemically modified in a variety of ways, therapeutic modalities.Interview with: to deliver drugs in a more specificJohn Howl, Professor of Molecular manner. Why should there be a closePharmacology, Director of cooperation between industry andPantechnia - Research Institute in academia?Healthcare Science, University ofWolverhampton Drug discovery experts have become The more willing to share ideas and resources by attending meetings andMany cell-penetrating peptides are giving presentations. This collaborationcurrently being developed and are will help in the development of new industryprobably just a step away from clinical drugs.trials and drug development, saysJohn Howl, Professor of Molecular Academics formulate and generate newPharmacology, Director of Pantechnia - leads, but in order for these to be is atResearch Institute in Healthcare converted into viable therapeutics orScience, University of Wolverhampton. diagnostics, support is needed fromThey can be made more cell type- pharmaceutical companies.specific by adding on homing motifs andother targeting devices to deliver drugs Only then can a variety of new a veryin a more specific manner, he adds. analogues of lead compounds be screened and taken to the next level. ByA speaker at the marcus evans working together, there is hope thatDiscovery Summit 2013, in Monte some leads will progress into early stage excitingCarlo, Monaco, 21 - 22 March, John clinical trials and the next peptideHowl shares his views on why blockbuster can be developed.drug discovery experts andpharmaceutical companies should What is the next step for the drug stagework together. discovery industry?What breakthrough discoveries can The industry is at a very exciting stage,you predict in the peptide field? as it is waiting for cell-penetrating peptides to be developed and adoptedDuring the last five years, there has as a generic delivery tool. Once thisbeen a renewed interest in peptides and happens, there will be a surge ofpeptide-based therapeutics and interest and the area of cell-penetratingdiagnostics. More scientists are looking peptides will be invigorated.
  2. 2. The Pharma Network – marcus About the Discovery Summit 2013 evans Summits group delivers peer-to-peer information on This unique forum will take place at the Le Méridien Beach Plaza, Monte Carlo, strategic matters, professional Monaco, 21 - 22 March, 2013. Offering much more than any conference, exhibition trends and breakthrough or trade show, this exclusive meeting will bring together esteemed industry thought innovations. leaders and solution providers to a highly focused and interactive networking event. The Summit includes presentations and interactive forums on building bridges from pre-clinical to clinical studies and designing open innovation platforms. Please note that the Summit is a closed business event and the Contact number of participants strictly limited. Maria Gregoriou, Journalist, marcus evans, Summits Division Tel: + 357 22 849 400 Email: For more information please send an email to All rights reserved. The above content may be republished or reproduced. Kindly inform us by sending an email to press@marcusevanscy.comAbout marcus evans Summitsmarcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discussstrategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity toindividually tailor their schedules of keynote presentations, think tanks, seminars and one-to-one business meetings.For more information, please visit: www.marcusevans.comUpcoming EventsEvolution Summit (North America) - www.evolutionsummit.comEvolution Summit (Europe) - www.evolution-summit.comTo view the web version of this interview, please click here: